|
Quinupristin/Dalfopristin (Synercid) |
Non formulary
P&T Review,
Synercid was removed
from the formulary due to its adverse reaction and drug interaction profile.
Please call the physician and recommend an an alternative below. Doxycycline and nitrofurantoin are
recommended for susceptible VRE lower urinary tract infections. Nitrofurantoin
is contraindicated if creatinine clearnance is less than 60 ml/min.
Linezolid is recommended
for treatment of documented serious
vancomycin resistant Enterococcus faecium infections when no other alternative
is available.
Linezolid is not
recommended for treatment of other documented infections unless the patient is
allergic/intolerant to all other antibiotics demonstrating activity against the
pathogen.
· Synercid’s
predominate ADRs are infusion site related, including pain, inflammation, edema
and thrombophlebitis, occurring in 75% of patients when Synercid was given
through a peripheral line. Infusion related ADRs are dose and concentration
dependent. Approximately 5% of patients have discontinued Syncercid due to
infusion site reactions. Central line infusion is preferred. Arthralgias and
myalgias are common and may be severe. Other ADRs include HA, GI disturbances,
non-local skin reactions, and LFT and bilirubin elevations up to 5 times the
upper limit of normal.
|